Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OC-IgT cells
- Development stage
- Unknown
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
OC-IgT cells are an autologous cell therapy product consisting of T cells that have been genetically modified (immunogene-modified) to target ovarian cancer. Developed by the Shenzhen Geno-Immune Medical Institute, the therapy involves the extraction of a patient's own T cells, which are then modified—typically using lentiviral vectors—to express specific therapeutic genes designed to enhance their anti-tumor activity against ovarian malignancies. This approach often utilizes the institute's 4th generation chimeric antigen receptor (4SCAR) technology. OC-IgT is currently being investigated in Phase 1/2 clinical trials for the treatment of high-risk Stage III-IV ovarian cancer, focusing on safety, persistence, and clinical efficacy.
- Other names
- Ovarian Cancer Immunogene-modified T cells
Beyond the preview
Go deeper on OC-IgT cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OC-IgT cells.